LHC: LMI targets rapid growth via NeuraCeq®, new diagnostics, and stable R&D revenue streams

About this update from Life Healthcare Group Holdings Limited

LMI is set for strong growth, leveraging NeuraCeq® expansion, a robust product pipeline, and stable R&D services. The company targets a $2.5B market, aiming for 20%-40% share and >$900M peak annual sales from new products. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Life Healthcare Group Holdings Limited